Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2

Daniel J. Jackson; William W. Busse; Leonard B. Bacharier; Meyer Kattan; George T. O'Connor; Robert A. Wood; Cynthia M. Visness; Stephen R. Durham; David Larson; Stephane Esnault; Carole Ober; Peter J. Gergen; Patrice Becker; Alkis Togias; James E. Gern; Mathew C. Altman

doi:10.1016/j.jaci.2020.04.009

Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2

Daniel J. Jackson
, William W. Busse
, Leonard B. Bacharier
, Meyer Kattan
, George T. O'Connor
, Robert A. Wood
, Cynthia M. Visness
, Stephen R. Durham
, David Larson
, Stephane Esnault
, Carole Ober
, Peter J. Gergen
, Patrice Becker
, Alkis Togias
, James E. Gern
, Mathew C. Altman

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	203-206.e3
Journal	Journal of Allergy and Clinical Immunology
Volume	146
Issue number	1
DOIs	https://doi.org/10.1016/j.jaci.2020.04.009
State	Published - Jul 2020

Access to Document

10.1016/j.jaci.2020.04.009

Cite this

Jackson, D. J., Busse, W. W., Bacharier, L. B., Kattan, M., O'Connor, G. T., Wood, R. A., Visness, C. M., Durham, S. R., Larson, D., Esnault, S., Ober, C., Gergen, P. J., Becker, P., Togias, A., Gern, J. E., & Altman, M. C. (2020). Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. Journal of Allergy and Clinical Immunology, 146(1), 203-206.e3. https://doi.org/10.1016/j.jaci.2020.04.009

@article{8ba9e8bd89b5474a935a9248d06f9cd7,

title = "Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2",

author = "Jackson, \{Daniel J.\} and Busse, \{William W.\} and Bacharier, \{Leonard B.\} and Meyer Kattan and O'Connor, \{George T.\} and Wood, \{Robert A.\} and Visness, \{Cynthia M.\} and Durham, \{Stephen R.\} and David Larson and Stephane Esnault and Carole Ober and Gergen, \{Peter J.\} and Patrice Becker and Alkis Togias and Gern, \{James E.\} and Altman, \{Mathew C.\}",

note = "Funding Information: This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Department of Health and Human Services, under grant numbers 1UM1AI114271-01, UM2AI117870, 5UM1AI114271-03, and UM1AI109565. Additional support was provided by the National Heart, Lung, and Blood Institute, NIH, through grant number RO1HL12384, and National Center for Advancing Translational Sciences, NIH, through grant numbers UL1TR001079, 1UL1TR001430, UL1TR001873, and UL1TR002345. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The co-authorship by Drs Gergen, Becker, and Togias on this publication does not necessarily constitute endorsement by the National Institute of Allergy and Infectious Diseases, the NIH or any other agency of the United States government. Disclosure of potential conflict of interest: D. J. Jackson reports grants from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)/National Heart, Lung and Blood Institute (NHLBI) and GlaxoSmithKline, as well as personal fees from Pfizer for data and safety and monitoring board participation and personal consulting fees from Novartis, Sanofi-Regeneron, GlaxoSmithKline, Vifor Pharma, and AstraZeneca. W. W. Busse reports grants from the NIH/NIAID/NHLBI during the conduct of the study, as well as personal fees from Novartis, Sandoz, Regeneron, AstraZeneca, GlaxoSmithKline, Genentech, Teva, Elsevier, Arrowhead, resTORbio, Med Learning Group, Practicing Clinicians Exchange, Boston Scientific, and Medscape. L. B. Bacharier reports grant support from the NIH/NIAID/NHLBI, Sanofi, and Vectura, as well as personal fees from GlaxoSmithKline, Genentech, Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi, Regeneron, Vectura, and Circassia. R. A. Wood receives grant support from the NIH, Astellas, Aimmune, DBV, Sanofi, and Regeneron, as well as royalties from Up To Date. J. E. Gern reports grants from the NIH; personal fees and stock options from Meissa Vaccines, Inc; personal fees from AstraZeneca and Ena Therapeutics; and a patent on methods for production of rhinoviruses. Dr. Altman reports personal fees from Regeneron for consulting. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) , Department of Health and Human Services , under grant numbers 1UM1AI114271-01, UM2AI117870 , 5UM1AI114271-03 , and UM1AI109565 . Additional support was provided by the National Heart, Lung, and Blood Institute , NIH, through grant number RO1HL12384 , and National Center for Advancing Translational Sciences , NIH, through grant numbers UL1TR001079 , 1UL1TR001430 , UL1TR001873 , and UL1TR002345 . Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The co-authorship by Drs Gergen, Becker, and Togias on this publication does not necessarily constitute endorsement by the National Institute of Allergy and Infectious Diseases, the NIH or any other agency of the United States government. ",

year = "2020",

month = jul,

doi = "10.1016/j.jaci.2020.04.009",

language = "English",

volume = "146",

pages = "203--206.e3",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

number = "1",

}

Jackson, DJ, Busse, WW, Bacharier, LB, Kattan, M, O'Connor, GT, Wood, RA, Visness, CM, Durham, SR, Larson, D, Esnault, S, Ober, C, Gergen, PJ, Becker, P, Togias, A, Gern, JE & Altman, MC 2020, 'Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2', Journal of Allergy and Clinical Immunology, vol. 146, no. 1, pp. 203-206.e3. https://doi.org/10.1016/j.jaci.2020.04.009

TY - JOUR

T1 - Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2

AU - Jackson, Daniel J.

AU - Busse, William W.

AU - Bacharier, Leonard B.

AU - Kattan, Meyer

AU - O'Connor, George T.

AU - Wood, Robert A.

AU - Visness, Cynthia M.

AU - Durham, Stephen R.

AU - Larson, David

AU - Esnault, Stephane

AU - Ober, Carole

AU - Gergen, Peter J.

AU - Becker, Patrice

AU - Togias, Alkis

AU - Gern, James E.

AU - Altman, Mathew C.

N1 - Funding Information: This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Department of Health and Human Services, under grant numbers 1UM1AI114271-01, UM2AI117870, 5UM1AI114271-03, and UM1AI109565. Additional support was provided by the National Heart, Lung, and Blood Institute, NIH, through grant number RO1HL12384, and National Center for Advancing Translational Sciences, NIH, through grant numbers UL1TR001079, 1UL1TR001430, UL1TR001873, and UL1TR002345. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The co-authorship by Drs Gergen, Becker, and Togias on this publication does not necessarily constitute endorsement by the National Institute of Allergy and Infectious Diseases, the NIH or any other agency of the United States government. Disclosure of potential conflict of interest: D. J. Jackson reports grants from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)/National Heart, Lung and Blood Institute (NHLBI) and GlaxoSmithKline, as well as personal fees from Pfizer for data and safety and monitoring board participation and personal consulting fees from Novartis, Sanofi-Regeneron, GlaxoSmithKline, Vifor Pharma, and AstraZeneca. W. W. Busse reports grants from the NIH/NIAID/NHLBI during the conduct of the study, as well as personal fees from Novartis, Sandoz, Regeneron, AstraZeneca, GlaxoSmithKline, Genentech, Teva, Elsevier, Arrowhead, resTORbio, Med Learning Group, Practicing Clinicians Exchange, Boston Scientific, and Medscape. L. B. Bacharier reports grant support from the NIH/NIAID/NHLBI, Sanofi, and Vectura, as well as personal fees from GlaxoSmithKline, Genentech, Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi, Regeneron, Vectura, and Circassia. R. A. Wood receives grant support from the NIH, Astellas, Aimmune, DBV, Sanofi, and Regeneron, as well as royalties from Up To Date. J. E. Gern reports grants from the NIH; personal fees and stock options from Meissa Vaccines, Inc; personal fees from AstraZeneca and Ena Therapeutics; and a patent on methods for production of rhinoviruses. Dr. Altman reports personal fees from Regeneron for consulting. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) , Department of Health and Human Services , under grant numbers 1UM1AI114271-01, UM2AI117870 , 5UM1AI114271-03 , and UM1AI109565 . Additional support was provided by the National Heart, Lung, and Blood Institute , NIH, through grant number RO1HL12384 , and National Center for Advancing Translational Sciences , NIH, through grant numbers UL1TR001079 , 1UL1TR001430 , UL1TR001873 , and UL1TR002345 . Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The co-authorship by Drs Gergen, Becker, and Togias on this publication does not necessarily constitute endorsement by the National Institute of Allergy and Infectious Diseases, the NIH or any other agency of the United States government.

PY - 2020/7

Y1 - 2020/7

UR - https://www.scopus.com/pages/publications/85084230022

U2 - 10.1016/j.jaci.2020.04.009

DO - 10.1016/j.jaci.2020.04.009

M3 - Article

C2 - 32333915

AN - SCOPUS:85084230022

SN - 0091-6749

VL - 146

SP - 203-206.e3

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 1

ER -

Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2

Access to Document

Other files and links

Cite this